Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Myers Michael	2. Date of Event Requiring Statement (MM/DD/YYYY) 1/1/2023	3. Issuer Name and Ticker or Trading Symbol Quoin Pharmaceuticals, Ltd. [QNRX]
(Last)        (First)        (Middle) AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, 132 MENACHEM BEGIN BLVD	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) Chief Executive Officer /
(Street) TEL AVIV, L3 6701101       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	561480000 (1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	4/12/2023 (2)	4/12/2032	Ordinary Shares	428571600 (3)	$0.0035 (3)	D

Explanation of Responses:
(1)	Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents five thousand (5,000) ordinary shares of the Issuer.
(2)	The option vests in four equal annual installments beginning on April 12, 2023.
(3)	The number of securities underlying the option and the exercise price are listed in terms of ordinary shares, with five thousand (5,000) ordinary shares of the Issuer represented by one (1) ADS, which evidences the grant of an option to buy 85,714.32 ADSs at the exercise price of $17.50 per ADS.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Myers Michael AZRIELI CENTER, ROUND TOWER, 30TH FLOOR 132 MENACHEM BEGIN BLVD TEL AVIV, L3 6701101	X		Chief Executive Officer

Signatures
/s/ Michael Myers		1/1/2023
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.